info icon

Adenocarcinoma, papilloma adenocarcinoma and mucinous carcinomas of rectum

C3_RECTUM_ADENO_MUCINO

No definition available.

Endpoint definition

FinnGen phenotype data

429209 individuals

diagram downward connector

Apply sex-specific rule None

429209

diagram downward connector

Check conditions None

429209

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Cause of death: ICD-10 C20.92&
Cancer registry: Topography ICD-O-3 C19|C20
Cancer registry: Morphology ICD-O-3 8140|8480
Cancer registry: Behaviour codes 3

2 out of 7 registries used, show all original rules.

2630

diagram downward connector

Check minimum number of events None

2630

diagram downward connector

Include endpoints None

2630

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

2545

diagram downward connector
C3_RECTUM_ADENO_MUCINO

Control definitions

Controls for this endpoint are individuals that are not cases.

Extra metadata

First used in FinnGen datafreeze DF9
Name in latin Carcinoma in situ cavitatis oris, oesophagi sive ventriculi

Similar endpoints

List of similar endpoints to Adenocarcinoma, papilloma adenocarcinoma and mucinous carcinomas of rectum based on the number of shared cases.

Venn diagram with an highlighted set fully inside another set Broader endpoints:

Venn diagram with a set fully inside an highlighted set Narrower endpoints:

Show all endpoint correlations

Summary Statistics

Key figures

All Female Male
Number of individuals 2545 909 1636
Unadjusted prevalence (%) 0.62 0.39 0.90
Mean age at first event (years) 66.82 64.94 67.87

Mortality

Not a core endpoint, no data to show.

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Not a core endpoint, no data to show.

Correlations

Index endpoint: C3_RECTUM_ADENO_MUCINO – Adenocarcinoma, papilloma adenocarcinoma and mucinous carcinomas of rectum
GWS hits:

Survival analyses between endpoints

Not a core endpoint, no data to show.

Drugs most likely to be purchased after Adenocarcinoma, papilloma adenocarcinoma and mucinous carcinomas of rectum

Endpoint not on priority list, no data to show.